about
Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisComparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysisOverall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis.Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatmentRisk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy
P50
Q27026453-A2189BCE-690D-44A7-9031-E689DEDF7D37Q28281529-20A23FBC-16E3-4AD5-B65B-158D06D78D6BQ30588681-850FD72C-3653-4252-99D2-DDEC1A2EDBC2Q33395482-BFDCB14D-D9B8-4354-8309-F7C13A57ED78Q33397197-7DEFA85C-5A6B-4508-AC06-50BF4896F081Q33399254-589447A1-A358-421F-B2B6-16DC3CD78918Q33400419-1EC32AF1-439D-449E-B0D6-2AF777BFA79DQ33401852-2EEBD034-7BEB-4992-BBDA-7311337FAC80Q33402854-EFC12345-4DEC-467A-B9D8-62527127ED04Q34762467-34C3267D-DB78-4B52-A675-AFF2C52B5EADQ36729895-4D919DAC-5271-4DB8-873A-ABFF0D7D9C10Q37161885-3A0115A5-2559-4C34-9666-1A12F58E0394Q37161889-323AD81F-5EFF-43BE-B86D-E46EAA1106A5Q37993216-D97B6B8B-1474-495B-8E31-FBCD750A75ADQ38034487-B09E93BF-5992-458A-BAFA-78AA8BC82462Q38065277-ECA45B78-B0FD-451F-B79C-7434229D9EE1Q38117931-74F9CE93-0AFF-405F-9B1D-3BAA0901D35CQ38124856-D6159402-21C1-4B73-A4EB-CFA0C59624EDQ38158401-BE2C032D-7376-4AFB-A100-DDA0BD89F848Q38184936-2384B53F-DC72-4C46-90F6-95491A71FEDAQ39514813-46CD3C5A-D39F-4B5D-8213-E6E93805BC9EQ43794742-7C455286-8EBA-4E22-A002-385EBCACBBECQ51021522-7058629D-B39D-47E2-A56D-90FAAD28C2B6Q51054919-89AD6F13-104D-48CC-B313-5950F8F278FEQ54386535-F7674A3B-4FE5-4D50-B33D-DCF2324C57CEQ90452566-AAB9D9F5-2C50-47F8-9D06-AA8BCF716BAFQ95291037-71939F9C-57C8-4BE7-87E7-67979116F583
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wei-xiang Qi
@ast
Wei-xiang Qi
@en
Wei-xiang Qi
@es
Wei-xiang Qi
@nl
Wei-xiang Qi
@sl
type
label
Wei-xiang Qi
@ast
Wei-xiang Qi
@en
Wei-xiang Qi
@es
Wei-xiang Qi
@nl
Wei-xiang Qi
@sl
prefLabel
Wei-xiang Qi
@ast
Wei-xiang Qi
@en
Wei-xiang Qi
@es
Wei-xiang Qi
@nl
Wei-xiang Qi
@sl
P106
P31
P496
0000-0001-5484-3343